BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/24/2022 9:30:38 AM | Browse: 757 | Download: 2121
Publication Name World Journal of Nephrology
Manuscript ID 67699
Country India
ISSN 2220-6124 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pharmacology & Pharmacy
Manuscript Type Minireviews
Article Title Reno protective role of amlodipine in patients with hypertensive chronic kidney disease
Manuscript Source Unsolicited Manuscript
All Author List Georgi Abraham, A Almeida, Kumar Gaurav, Mohammed Yunus Khan, Usha Rani Patted and Maithrayie Kumaresan
Funding Agency and Grant Number
Corresponding Author Mohammed Yunus Khan, MD, N/A, N/A, Medical Affairs, Dr. Reddys Labs, 7-1, 27, Ameerpet Rd, Leelanagar, Ameerpet,, Hyderabad 500016, Telangana, India. doctorkhan26@gmail.com
Key Words Albumin-to-alkaline phosphatase ratio; Gastric cancer; overall survival; Progression-free survival
Core Tip Amlodipine (ALM) is a powerful, well-tolerated, and safe anti-hypertensive agent widely used alone or as a key component of combination therapy for hypertension in chronic kidney disease (CKD). Its effectiveness in reducing blood pressure has proven benefits in cardiovascular event reduction and progression of renal disease. Overall, ALM emerges as the drug of choice in comparison to the newer calcium channel blockers in terms of its effectiveness and potency in BP lowering in CKD patients.
Publish Date 2022-05-24 08:03
Citation Li YT, Zhou XS, Han XM, Tian J, Qin Y, Zhang T, Liu JL. Reno protective role of amlodipine in patients with hypertensive chronic kidney disease. World J Gastrointest Oncol 2021; 11(3): 86-95
URL https://www.wjgnet.com/2220-6124/full/v11/i3/86.htm
DOI https://dx.doi.org/10.5527/wjn.v11.i3.86
Full Article (PDF) WJN-11-86.pdf
Full Article (Word) WJN-11-86.docx